Switch to:
Also traded in: Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.58
BIIB's Cash to Debt is ranked lower than
86% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. BIIB: 0.58 )
Ranked among companies with meaningful Cash to Debt only.
BIIB' s Cash to Debt Range Over the Past 10 Years
Min: 0.25  Med: 1.49 Max: 28.5
Current: 0.58
0.25
28.5
Equity to Asset 0.53
BIIB's Equity to Asset is ranked lower than
70% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. BIIB: 0.53 )
Ranked among companies with meaningful Equity to Asset only.
BIIB' s Equity to Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.75 Max: 0.84
Current: 0.53
0.48
0.84
Interest Coverage 25.35
BIIB's Interest Coverage is ranked lower than
69% of the 365 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BIIB: 25.35 )
Ranked among companies with meaningful Interest Coverage only.
BIIB' s Interest Coverage Range Over the Past 10 Years
Min: 19.25  Med: 43.52 Max: 505.19
Current: 25.35
19.25
505.19
F-Score: 5
Z-Score: 6.28
M-Score: -2.86
WACC vs ROIC
3.67%
32.52%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 47.86
BIIB's Operating margin (%) is ranked higher than
96% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -77.71 vs. BIIB: 47.86 )
Ranked among companies with meaningful Operating margin (%) only.
BIIB' s Operating margin (%) Range Over the Past 10 Years
Min: 9.74  Med: 29.61 Max: 40.77
Current: 47.86
9.74
40.77
Net-margin (%) 33.97
BIIB's Net-margin (%) is ranked higher than
94% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -78.92 vs. BIIB: 33.97 )
Ranked among companies with meaningful Net-margin (%) only.
BIIB' s Net-margin (%) Range Over the Past 10 Years
Min: 6.63  Med: 21.74 Max: 30.25
Current: 33.97
6.63
30.25
ROE (%) 35.19
BIIB's ROE (%) is ranked higher than
97% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. BIIB: 35.19 )
Ranked among companies with meaningful ROE (%) only.
BIIB' s ROE (%) Range Over the Past 10 Years
Min: 2.34  Med: 16.72 Max: 30.21
Current: 35.19
2.34
30.21
ROA (%) 19.25
BIIB's ROA (%) is ranked higher than
96% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. BIIB: 19.25 )
Ranked among companies with meaningful ROA (%) only.
BIIB' s ROA (%) Range Over the Past 10 Years
Min: 1.83  Med: 11.74 Max: 22.42
Current: 19.25
1.83
22.42
ROC (Joel Greenblatt) (%) 181.90
BIIB's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. BIIB: 181.90 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BIIB' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 12.15  Med: 64.76 Max: 183.46
Current: 181.9
12.15
183.46
Revenue Growth (3Y)(%) 25.70
BIIB's Revenue Growth (3Y)(%) is ranked higher than
80% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. BIIB: 25.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BIIB' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.5  Med: 24.45 Max: 78.2
Current: 25.7
-2.5
78.2
EBITDA Growth (3Y)(%) 31.80
BIIB's EBITDA Growth (3Y)(%) is ranked higher than
84% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. BIIB: 31.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BIIB' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -18.6  Med: 33.45 Max: 82.3
Current: 31.8
-18.6
82.3
EPS Growth (3Y)(%) 34.90
BIIB's EPS Growth (3Y)(%) is ranked higher than
87% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. BIIB: 34.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BIIB' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -66  Med: 37.95 Max: 205.4
Current: 34.9
-66
205.4
» BIIB's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-21)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

BIIB Guru Trades in Q3 2015

Ray Dalio 14,766 sh (New)
John Burbank 10,551 sh (New)
Joel Greenblatt 9,410 sh (New)
Steven Cohen 6,800 sh (New)
Richard Snow 45,861 sh (+336.77%)
Vanguard Health Care Fund 3,666,723 sh (+105.96%)
Signature Select Canadian Fund 7,900 sh (+43.64%)
Ken Fisher 112,448 sh (+38.94%)
Ron Baron 11,814 sh (+29.20%)
Mario Gabelli 4,797 sh (unchged)
Mairs and Power 1,095 sh (unchged)
Pioneer Investments Sold Out
RS Investment Management Sold Out
Paul Tudor Jones Sold Out
Andreas Halvorsen Sold Out
PRIMECAP Management 15,843,460 sh (-3.99%)
Murray Stahl 7,713 sh (-7.44%)
Frank Sands 4,121,400 sh (-12.92%)
Jeremy Grantham 179,221 sh (-28.61%)
Jim Simons 34,961 sh (-66.79%)
» More
Q4 2015

BIIB Guru Trades in Q4 2015

John Buckingham 17,389 sh (New)
John Paulson 36,200 sh (New)
Jeff Auxier 7,195 sh (New)
First Eagle Investment 193,885 sh (New)
Paul Tudor Jones 4,368 sh (New)
Andreas Halvorsen 368,864 sh (New)
Steven Cohen 86,700 sh (+1175.00%)
Joel Greenblatt 84,577 sh (+798.80%)
Ray Dalio 25,106 sh (+70.03%)
Vanguard Health Care Fund 3,810,023 sh (+3.91%)
Mario Gabelli 4,805 sh (+0.17%)
Mairs and Power 1,095 sh (unchged)
Samuel Isaly 200,000 sh (unchged)
Jim Simons Sold Out
John Burbank Sold Out
Murray Stahl 7,705 sh (-0.10%)
PRIMECAP Management 15,810,625 sh (-0.21%)
Ken Fisher 110,475 sh (-1.75%)
Richard Snow 40,290 sh (-12.15%)
Ron Baron 10,240 sh (-13.32%)
Frank Sands 3,367,531 sh (-18.29%)
Jeremy Grantham 98,334 sh (-45.13%)
» More
Q1 2016

BIIB Guru Trades in Q1 2016

Lee Ainslie 9,370 sh (New)
Pioneer Investments 880 sh (New)
Ronald Muhlenkamp 23,853 sh (New)
Jim Simons 127,661 sh (New)
Joel Greenblatt 298,673 sh (+253.14%)
John Paulson 118,400 sh (+227.07%)
Richard Snow 91,801 sh (+127.85%)
Ron Baron 16,047 sh (+56.71%)
Jeff Auxier 9,015 sh (+25.30%)
Steven Cohen 102,200 sh (+17.88%)
First Eagle Investment 224,585 sh (+15.83%)
PRIMECAP Management 16,246,726 sh (+2.76%)
Mario Gabelli 4,810 sh (+0.10%)
Vanguard Health Care Fund 3,810,023 sh (unchged)
Murray Stahl 7,705 sh (unchged)
Ronald Muhlenkamp 3,000 sh (unchged)
Samuel Isaly 200,000 sh (unchged)
Signature Select Canadian Fund Sold Out
John Buckingham 16,809 sh (-3.34%)
Mairs and Power 1,025 sh (-6.39%)
Frank Sands 3,141,109 sh (-6.72%)
Ray Dalio 23,106 sh (-7.97%)
Ken Fisher 90,405 sh (-18.17%)
Andreas Halvorsen 230,947 sh (-37.39%)
Paul Tudor Jones 1,000 sh (-77.11%)
Jeremy Grantham 1,380 sh (-98.60%)
» More
2016

BIIB Guru Trades in 2016

Spiros Segalas 1,280,832 sh (unchged)
Samuel Isaly 176,000 sh (-12.00%)
» More
» Details

Insider Trades

Latest Guru Trades with BIIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:CELG, NAS:REGN, OTCPK:CSLLY, OTCPK:SHPGF, NYSE:BXLT, NAS:ALXN, NAS:VRTX, OTCPK:ALIOY, NAS:INCY, NAS:BMRN, OTCPK:GIKLY, OTCPK:NVZMY, OTCPK:UCBJY, NAS:GILD, NAS:MDVN, OTCPK:GMXAY, NAS:JAZZ, NAS:ALKS, NAS:SGEN, NAS:ALNY » details
Traded in other countries:BIIB34.Brazil, IDP.Germany, BIIB.Mexico, BIIB.Switzerland, 0R1B.UK,
Biogen Idec Inc, is a biopharmaceutical company. The Company discovers, develops, manufactures and markets therapies for neurological, autoimmune and hematologic disorders.

Biogen Inc was founded in 1978 in the state if Delaware. In March 2015, its name changed from Biogen Idec Inc. to Biogen Inc. It is a biotechnology company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. It also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions. The Company's marketed products include MA Products, AVONEX; TYSABRI; RITUXAN; FAMPYRA; FUMADERM. The Company develop, manufacture and market a number of products designed to treat patients with MS. MS is a progressive neurological disease in which the body loses the ability to transmit messages along nerve cells, to a loss of muscle control, paralysis and, in some cases, death. AVONEX is one of the prescribed treatments for relapsing forms of MS. TYSABRI has the treatment of relapsing MS with its established efficacy. TYSABRI is a monoclonal antibody approved in numerous countries as a monotherapy treatment for relapsing MS and also approved in the U.S. to treat Crohn's disease, an inflammatory disease of the intestines. RITUXAN is a prescribed monoclonal antibody therapeutic used to treat non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia and two forms of ANCA-associated vasculitis. FAMPYRA is the first treatment that addresses the unmet medical need of walking improvement in adult patients with MS who have walking disability. FAMPYRA is a prolonged-release tablet formulation of the drug fampridine. The Company is facing competition from other biotechnology firms and large pharmaceutical companies. The Company is subject to various federal and state laws pertaining to health care fraud and abuse, including anti-kickback laws and false claims laws.

Ratios

vs
industry
vs
history
P/E(ttm) 16.96
BIIB's P/E(ttm) is ranked higher than
72% of the 254 Companies
in the Global Biotechnology industry.

( Industry Median: 29.09 vs. BIIB: 16.96 )
Ranked among companies with meaningful P/E(ttm) only.
BIIB' s P/E(ttm) Range Over the Past 10 Years
Min: 11.73  Med: 26.28 Max: 477.1
Current: 16.96
11.73
477.1
Forward P/E 15.63
BIIB's Forward P/E is ranked higher than
68% of the 71 Companies
in the Global Biotechnology industry.

( Industry Median: 21.32 vs. BIIB: 15.63 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 16.96
BIIB's PE(NRI) is ranked higher than
72% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 29.71 vs. BIIB: 16.96 )
Ranked among companies with meaningful PE(NRI) only.
BIIB' s PE(NRI) Range Over the Past 10 Years
Min: 11.73  Med: 26.28 Max: 530.11
Current: 16.96
11.73
530.11
Price/Owner Earnings (ttm) 23.87
BIIB's Price/Owner Earnings (ttm) is ranked higher than
65% of the 130 Companies
in the Global Biotechnology industry.

( Industry Median: 34.88 vs. BIIB: 23.87 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
BIIB' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.81  Med: 26.76 Max: 158.54
Current: 23.87
10.81
158.54
P/B 5.57
BIIB's P/B is ranked lower than
72% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. BIIB: 5.57 )
Ranked among companies with meaningful P/B only.
BIIB' s P/B Range Over the Past 10 Years
Min: 1.86  Med: 3.92 Max: 9.6
Current: 5.57
1.86
9.6
P/S 5.83
BIIB's P/S is ranked higher than
70% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 12.77 vs. BIIB: 5.83 )
Ranked among companies with meaningful P/S only.
BIIB' s P/S Range Over the Past 10 Years
Min: 2.81  Med: 6.03 Max: 11.94
Current: 5.83
2.81
11.94
PFCF 20.33
BIIB's PFCF is ranked higher than
63% of the 147 Companies
in the Global Biotechnology industry.

( Industry Median: 27.27 vs. BIIB: 20.33 )
Ranked among companies with meaningful PFCF only.
BIIB' s PFCF Range Over the Past 10 Years
Min: 10.14  Med: 21.70 Max: 39.29
Current: 20.33
10.14
39.29
POCF 16.81
BIIB's POCF is ranked higher than
61% of the 205 Companies
in the Global Biotechnology industry.

( Industry Median: 22.90 vs. BIIB: 16.81 )
Ranked among companies with meaningful POCF only.
BIIB' s POCF Range Over the Past 10 Years
Min: 7.95  Med: 17.99 Max: 35.29
Current: 16.81
7.95
35.29
EV-to-EBIT 12.32
BIIB's EV-to-EBIT is ranked higher than
63% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 20.49 vs. BIIB: 12.32 )
Ranked among companies with meaningful EV-to-EBIT only.
BIIB' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.2  Med: 18.35 Max: 68.3
Current: 12.32
8.2
68.3
EV-to-EBITDA 11.05
BIIB's EV-to-EBITDA is ranked higher than
64% of the 319 Companies
in the Global Biotechnology industry.

( Industry Median: 17.75 vs. BIIB: 11.05 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIIB' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.6  Med: 14.60 Max: 27
Current: 11.05
6.6
27
PEG 0.65
BIIB's PEG is ranked higher than
85% of the 89 Companies
in the Global Biotechnology industry.

( Industry Median: 2.22 vs. BIIB: 0.65 )
Ranked among companies with meaningful PEG only.
BIIB' s PEG Range Over the Past 10 Years
Min: 0.34  Med: 1.03 Max: 48.49
Current: 0.65
0.34
48.49
Shiller P/E 40.76
BIIB's Shiller P/E is ranked higher than
63% of the 54 Companies
in the Global Biotechnology industry.

( Industry Median: 56.77 vs. BIIB: 40.76 )
Ranked among companies with meaningful Shiller P/E only.
BIIB' s Shiller P/E Range Over the Past 10 Years
Min: 32.17  Med: 85.65 Max: 1717
Current: 40.76
32.17
1717
Current Ratio 2.96
BIIB's Current Ratio is ranked lower than
69% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. BIIB: 2.96 )
Ranked among companies with meaningful Current Ratio only.
BIIB' s Current Ratio Range Over the Past 10 Years
Min: 0.78  Med: 3.29 Max: 17.39
Current: 2.96
0.78
17.39
Quick Ratio 2.56
BIIB's Quick Ratio is ranked lower than
69% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. BIIB: 2.56 )
Ranked among companies with meaningful Quick Ratio only.
BIIB' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 2.89 Max: 16.79
Current: 2.56
0.7
16.79
Days Inventory 255.56
BIIB's Days Inventory is ranked lower than
81% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 128.57 vs. BIIB: 255.56 )
Ranked among companies with meaningful Days Inventory only.
BIIB' s Days Inventory Range Over the Past 10 Years
Min: 211.91  Med: 234.74 Max: 266.3
Current: 255.56
211.91
266.3
Days Sales Outstanding 41.99
BIIB's Days Sales Outstanding is ranked higher than
63% of the 607 Companies
in the Global Biotechnology industry.

( Industry Median: 62.37 vs. BIIB: 41.99 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIIB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.79  Med: 44.30 Max: 48.62
Current: 41.99
39.79
48.62
Days Payable 62.22
BIIB's Days Payable is ranked higher than
61% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 57.77 vs. BIIB: 62.22 )
Ranked among companies with meaningful Days Payable only.
BIIB' s Days Payable Range Over the Past 10 Years
Min: 71.43  Med: 105.99 Max: 148.21
Current: 62.22
71.43
148.21

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 14.88
BIIB's Price/Tangible Book is ranked lower than
90% of the 1012 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. BIIB: 14.88 )
Ranked among companies with meaningful Price/Tangible Book only.
BIIB' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.91  Med: 6.34 Max: 26.82
Current: 14.88
0.91
26.82
Price/Projected FCF 1.86
BIIB's Price/Projected FCF is ranked higher than
69% of the 201 Companies
in the Global Biotechnology industry.

( Industry Median: 3.44 vs. BIIB: 1.86 )
Ranked among companies with meaningful Price/Projected FCF only.
BIIB' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.65  Med: 2.10 Max: 25.99
Current: 1.86
0.65
25.99
Price/DCF (Earnings Based) 0.59
BIIB's Price/DCF (Earnings Based) is ranked higher than
87% of the 16 Companies
in the Global Biotechnology industry.

( Industry Median: 1.47 vs. BIIB: 0.59 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.96
BIIB's Price/Median PS Value is ranked lower than
52% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. BIIB: 0.96 )
Ranked among companies with meaningful Price/Median PS Value only.
BIIB' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.23  Med: 0.99 Max: 15.72
Current: 0.96
0.23
15.72
Price/Peter Lynch Fair Value 0.68
BIIB's Price/Peter Lynch Fair Value is ranked higher than
83% of the 65 Companies
in the Global Biotechnology industry.

( Industry Median: 1.76 vs. BIIB: 0.68 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
BIIB' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.44  Med: 1.38 Max: 20.5
Current: 0.68
0.44
20.5
Price/Graham Number 3.34
BIIB's Price/Graham Number is ranked lower than
62% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 2.88 vs. BIIB: 3.34 )
Ranked among companies with meaningful Price/Graham Number only.
BIIB' s Price/Graham Number Range Over the Past 10 Years
Min: 0.6  Med: 3.28 Max: 36.53
Current: 3.34
0.6
36.53
Earnings Yield (Greenblatt) (%) 8.13
BIIB's Earnings Yield (Greenblatt) (%) is ranked higher than
90% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. BIIB: 8.13 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BIIB' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.5  Med: 5.45 Max: 12.3
Current: 8.13
1.5
12.3
Forward Rate of Return (Yacktman) (%) 34.23
BIIB's Forward Rate of Return (Yacktman) (%) is ranked higher than
82% of the 114 Companies
in the Global Biotechnology industry.

( Industry Median: 14.20 vs. BIIB: 34.23 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BIIB' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -4.6  Med: 26.15 Max: 45.3
Current: 34.23
-4.6
45.3

More Statistics

Revenue (TTM) (Mil) $11,238
EPS (TTM) $ 17.14
Beta0.28
Short Percentage of Float1.18%
52-Week Range $223.02 - 338.51
Shares Outstanding (Mil)219.12

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 11,513 12,415 13,340
EPS ($) 18.45 20.34 22.53
EPS w/o NRI ($) 18.45 20.34 22.53
EPS Growth Rate
(3Y to 5Y Estimate)
8.28%
Dividends Per Share ($)
» More Articles for NAS:BIIB

Headlines

Articles On GuruFocus.com
The Neglected Biogen Jun 13 2016 
5 Attractive Biotechnology Stocks for Healthy Long-term Returns Jun 10 2016 
High Quality Stocks Gurus Are Buying Jun 07 2016 
Joel Greenblatt Bets on eBay, Intel, Biogen Jun 03 2016 
Jeff Auxier's Spring 2016 Market Commentary May 20 2016 
Richard Snow Boosts Biogen, Keysight Technologies May 12 2016 
10 Years of Strong Returns: Priceline, Biogen Apr 26 2016 
Alaska Air, Delta and NVR Make the 30-30 Club Apr 15 2016 
Undervalued Stocks With Wide Margin of Safety Apr 14 2016 
John Buckingham Trades in ETFs in 4th Quarter Mar 15 2016 

More From Other Websites
BUZZ-U.S. stocks weekly: Don't drink and drive Jul 29 2016
7 Quality Stocks That Don’t Pay a Dividend (PCLN) Jul 29 2016
Biotech Stocks: The End of Political Risk? Jul 29 2016
BIOGEN INC. Financials Jul 28 2016
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene Jul 28 2016
What Will Be a Key Driver of Biogen’s Future Valuations? Jul 28 2016
Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure Jul 27 2016
Biogen Misses EndPoints in Synergy Trial for Opicinumab Jul 27 2016
BIIB Continues to Lead the MS Treatment Market in the US in 2016 Jul 27 2016
Major Biotechs See Increased Short Interest Bets Jul 27 2016
Tecfidera Is Still a Key Growth Driver for Biogen in 2016 Jul 26 2016
What’s Boosted Investors’ Confidence in Biogen in 2016? Jul 26 2016
What Are Analysts’ Recommendations for Biogen in 2016? Jul 25 2016
How Do Biogen’s Valuation Multiples Compare with Its Peers’? Jul 25 2016
Fresh Research Reports For Intel (INTC), AT&T (T) & Others Jul 25 2016
ETF’s with exposure to Biogen, Inc. : July 22, 2016 Jul 22 2016
Biogen (BIIB) Stock Up on CEO Transition, Fueling Sale Speculation Jul 22 2016
Six Major Biotech Acquisitions You Could See in 2016 (Part 2) Jul 22 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)